Premium
Urotensin II receptor expression in prostate cancer patients: A new possible marker
Author(s) -
Giulianelli Roberto,
Nardoni Stefano,
Falavolti Cristina,
Mirabile Gabriella,
Bellangino Mariangela,
Tema Giorgia,
Gentile Barbara Cristina,
Albanesi Luca,
Buscarini Maurizio,
Tariciotti Paola,
Lombardo Riccardo
Publication year - 2019
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23734
Subject(s) - prostate cancer , prostate , medicine , receptor , cancer , urotensin ii , pathology , oncology , cancer research , endocrinology
Background Urotensin II receptor has been poorly studied in prostate cancer. To evaluate the expression of urotensin II receptor (UII‐R) in patients undergoing radical prostatectomy. Methods Overall, we identified 140 patients treated with retropubic radical prostatectomy (RP) in one center. UII‐R was evaluated in prostate biopsies with immunohistochemical staining, resulting in a granular cytoplasmic positivity, through automated system using the kit Urotensin II Receptor Detection System provided by Pharmabullet srl. Immunostained slides were independently and blindly evaluated by ten uro‐pathologists. To evaluate UTII‐R expression three different parameters were considered: localization, granules dimensions and intensity of expression. A score from 0 to 3 was applied to each parameter to obtain a score from 0 to 9. Each parameter and the total score were evaluated as predictors of high grade disease on surgical pathology and of advanced stage disease. Accuracy of total score for the prediction of upgrading and upstaging was analyzed using receiver operator characteristics curve and decision curve analysis (DCA). Results On radical prostatectomy 92/140 (66%) presented high grade disease on surgical pathology. Patients with high grade disease presented an apical distribution of the receptor, larger granules and a more intense expression when compared to patients with low grade disease. A well they presented a higher total score. Subscores and total scores were found to be predictors of upgrading and upstaging. On ROC analysis total score presented an AUC of 0.72 and 0.70, respectively, for the prediction of upgrading and upstaging. On DCA total score showed a clinical benefit in the prediction of adverse pathological outcomes. Conclusion Urotensin II receptor is a potential marker of adverse pathological outcomes. Further studies should confirm our data and evaluate its role as a prognostic marker.